Refractory T-Cell Lymphoma
6 clinical trials · Condition
◉ Watch Refractory T-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NCT04217317) | Wake Forest University Health Sciences | 2020-09-16 |
| Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH (NCT04251065) | Fondazione Italiana Linfomi - ETS | 2020-09-03 |
| CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies (NCT04162340) | iCell Gene Therapeutics | 2019-07-11 |
| A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01878708) | Dana-Farber Cancer Institute | 2013-07-01 |
Track Refractory T-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.